Leadership team
Pheon has a very strong leadership team of specialists, bringing together the best of clinical and managerial expertise with a proven track record in targeted oncology therapies and ADCs.
Cyrus Mozayeni
Chief Executive Officer
Cyrus has over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth. He was previously an Entrepreneur-in-Residence at Atlas Venture, where he launched Vedere Bio, Inc. and Vedere Bio II, Inc., serving as CEO of both companies from inception through its sale to Novartis, in a deal valued at $280 million.
Prior to Atlas Venture, he was co-founder of CODA Biotherapeutics, and Oncorus, where he served as President and CBO. Before Oncorus, Cyrus was VP and Global Head of Business Development and Alliance Management at Bluebird Bio (NASDAQ: BLUE), where his efforts led to a clinical-stage CAR T-cell program (ABECMAÒ, idecabtagene vicleucel) in collaboration with Celgene, and a successful IPO.
Cyrus earned a Sc.B. in neuroscience from Brown University, M.D. from the University of Virginia School of Medicine and MBA from the Kellogg School of Management at Northwestern University. He is a licensed physician, a Fellow of the Academy of Wilderness Medicine, and is based in Cambridge, Massachusetts.
